KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Shares Outstanding (Diluted Average) (2017 - 2025)

Historic Shares Outstanding (Diluted Average) for Ionis Pharmaceuticals (IONS) over the last 15 years, with Q3 2025 value amounting to $159.8 million.

  • Ionis Pharmaceuticals' Shares Outstanding (Diluted Average) rose 751.85% to $159.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $159.8 million, marking a year-over-year increase of 751.85%. This contributed to the annual value of $149.5 million for FY2024, which is 441.65% up from last year.
  • As of Q3 2025, Ionis Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $159.8 million, which was up 751.85% from $182.3 million recorded in Q2 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Shares Outstanding (Diluted Average) peaked at $182.3 million during Q2 2025, and registered a low of $140.8 million during Q1 2021.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $147.0 million, with a median of $143.1 million in 2023.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first skyrocketed by 57.46% in 2022, then surged by 2492.02% in 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarter) stood at $141.0 million in 2021, then rose by 0.59% to $141.8 million in 2022, then grew by 0.95% to $143.2 million in 2023, then grew by 4.42% to $149.5 million in 2024, then rose by 6.86% to $159.8 million in 2025.
  • Its last three reported values are $159.8 million in Q3 2025, $182.3 million for Q2 2025, and $158.7 million during Q1 2025.